| Literature DB >> 2181334 |
J M Gilsbach1, H J Reulen, B Ljunggren, L Brandt, H von Holst, M Mokry, C von Essen, M A Conzen.
Abstract
A European, multicenter, prospective, randomized, double-blind, dose-comparison study on preventive therapy with intravenously administered nimodipine was performed to evaluate the efficacy and tolerability of two different doses: 2 and 3 mg/h. Two hundred four patients fulfilled the criteria for enrollment in the study: surgery within 72 hours after the last subarachnoid hemorrhage, and age between 16 and 72 years. All patients who had Hunt and Hess grades of I to III were operated upon; patients who had poor Hunt and Hess grades (IV-V) were operated on according to the surgeon's choice. This treatment regimen was associated with a low incidence of delayed neurological dysfunction with no significant difference between the two dosage groups: three patients (1.5%) remained severely disabled and two (1%) moderately disabled due to vasospasm with or without additional complications. Among the patients with Hunt and Hess grades of IV or V, the long-term outcome was favorable (good-fair) for 40% and unfavorable for 60%. Among the patients with grades of I to III, the long-term outcome was favorable for 89% and unfavorable for 11%.Entities:
Mesh:
Substances:
Year: 1990 PMID: 2181334 DOI: 10.1097/00006123-199003000-00013
Source DB: PubMed Journal: Neurosurgery ISSN: 0148-396X Impact factor: 4.654